Eric Coldwell
Stock Analyst at Baird
(3.52)
# 739
Out of 5,182 analysts
168
Total ratings
57.63%
Success rate
2.25%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Outperform | $565 → $477 | $421.37 | +13.20% | 20 | Apr 24, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $224 → $229 | $196.63 | +16.46% | 12 | Apr 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $10.60 | +50.94% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $263.43 | +23.75% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.23 | +6.12% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $828.32 | +11.91% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $171.23 | +16.22% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $163.84 | +57.47% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $103.21 | +117.03% | 22 | Sep 2, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $202.34 | +0.33% | 13 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $13.08 | +22.32% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $62.85 | -28.40% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $78.36 | -15.77% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.90 | +5,017.37% | 4 | Nov 10, 2017 |
Medpace Holdings
Apr 24, 2026
Maintains: Outperform
Price Target: $565 → $477
Current: $421.37
Upside: +13.20%
Quest Diagnostics
Apr 22, 2026
Maintains: Neutral
Price Target: $224 → $229
Current: $196.63
Upside: +16.46%
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $10.60
Upside: +50.94%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $263.43
Upside: +23.75%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.23
Upside: +6.12%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $828.32
Upside: +11.91%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $171.23
Upside: +16.22%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $163.84
Upside: +57.47%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $103.21
Upside: +117.03%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $202.34
Upside: +0.33%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $13.08
Upside: +22.32%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $62.85
Upside: -28.40%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $78.36
Upside: -15.77%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.90
Upside: +5,017.37%